Generic Medicine Info
Indications and Dosage
Adult: 150-250 mg bid, after breakfast and lunch. Maintenance: Doses may be given on alternate days. Max: 300 mg daily.

Adult: In combination w/ other diuretics (e.g. hydrochlorothiazide): Initially, 50 mg daily.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Should be taken with food.
Pre-existing or drug-induced hyperkalaemia, anuria, Addison's disease. Severe renal and hepatic impairment. Concomitant use w/ other K-sparing agents, K supplements.
Special Precautions
Patient w/ DM, hyperuricaemia or gout, history of renal calculi. Renal and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Photosensitivity reactions, blood dyscrasias, renal calculi, megaloblastic anaemia, reversible renal failure, increase in uric acid concentration, GI disturbances (e.g. nausea, vomiting, diarrhoea), hypotension, dizziness, weakness, headache, dry mouth, muscle cramps, anaphylaxis, rash.
Potentially Fatal: Hyperkalaemia.
Patient Counseling Information
May cause a blue fluorescence of the urine under certain light conditions.
Monitoring Parameters
Monitor serum electrolytes (esp K) frequently, BP, renal function.
Symptoms: Electrolyte imbalance esp hyperkalaemia, GI disturbances (e.g. nausea, vomiting), weakness, hypotension. Management: Induced gastric lavage or emesis. Admin pressor agents (e.g. norepinephrine) for severe hypotension. May perform dialysis.
Drug Interactions
May reduce antihypertensive effect w/ NSAIDs. May increase hyperkalaemic effect of ACE inhibitors. May increase risk of lithium toxicity. Increased risk of postural hypotension w/ TCAs. Increased risk of hyponatraemia w/ carbamazepine. May increase nephrotoxic effect w/ indometacin.
Potentially Fatal: May increase risk of hyperkalaemia w/ other K-sparing agents, K supplements.
Lab Interference
May interfere w/ the methods of enzyme assay that depend on fluorometry (e.g. determination of lactic dehydrogenase activity). Interferes w/ fluorometric assay of quinidine and bioassay of folic acid.
Description: Triamterene is a weak K-sparing diuretic which appears to act mainly on the distal renal tubules. It increases the excretion of Na, Mg, Ca, bicarbonate and decreases K excretion. It adds to the natriuretic but reduces the kaliuretic effects of other diuretics.
Onset: Diuresis: 2-4 hr.
Duration: Diuresis: 7-9 hr.
Absorption: Variably but fairly rapidly absorbed from the GI tract. Bioavailability: Approx 50%. Time to peak plasma concentration: 3 hr.
Distribution: Crosses the placenta; enters breast milk. Plasma protein binding: Approx 60%.
Metabolism: Extensively metabolised by CYP1A2 isoenzyme to the sulfate conjugate of hydroxytriamterene.
Excretion: Via urine (21% to <50%, mainly as metabolites). Plasma half-life: Approx 2 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Triamterene, CID=5546, (accessed on Jan. 23, 2020)

Store between 15-30°C.
MIMS Class
ATC Classification
C03DB02 - triamterene ; Belongs to the class of other potassium-sparing agents. Used as diuretics.
Anon. Triamterene. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 12/11/2014.

Buckingham R (ed). Triamterene. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 12/11/2014.

Dyrenium Capsule (WellSpring Pharmaceutical Corporation). DailyMed. Source: U.S. National Library of Medicine. Accessed 12/11/2014.

Joint Formulary Committee. Triamterene. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 12/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Triamterene. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 12/11/2014.

Disclaimer: This information is independently developed by MIMS based on Triamterene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in